Kaufkurse nach Split im Verhältnis 1:350 ? oder ! - 500 Beiträge pro Seite

[64Dieter]

Zann hat Ende letzter Woche einen Split durchgeführt im Verhältnis 1:350 -
und vor kurzem unten stehende Nachricht veröffentlicht:

Könnte man jetzt einen Einstieg wagen - oder handelt es sich hier um "Schrott"?


Danke

64Dieter




ZANN Corp. Reports on Antibody Development Success
ZANN Corp. Reports on Antibody Development Success

BW5217 MAR 04,2005 6:50 PACIFIC 09:50 EASTERN

( BW)(MI-ZANN)(ZANN) ZANN Corp. Reports on Antibody DevelopmentSuccess

Business Editors/Health/Medical Writers

FENTON, Mich.--(BUSINESS WIRE)--March 4, 2005--ZANN Corp.(OTCBB:ZANN) announced today that they now have initial success indeveloping effective specific antibodies against one major species ofbacteria found in human blood. The commercial value of thisachievement has significant upside potential both in medicaldiagnostics and gene therapy products.
According to Luther E. Lindner, MD, PhD, Chief Medical Officer,"ZANN Corp.´s scientists (formerly Pathobiotek) have been culturingand characterizing a set of bacteria that they found to be generallypresent in the human bloodstream. Their characterization to date hasbeen reported at five (ASM, Pathologists and Blood) scientific/medicalmeetings. One species is now in continuous culture and another majorspecies is nearly in continuous culture. As the culture systemimproves, their properties, particularly their ability to persist inthe bloodstream, have attractive potential for their development as aplatform for some types of gene therapy.
"We have been collaborating with another company for thedevelopment of our monoclonal antibodies directed against two majorspecies of bacteria. The role of these bacteria in disease is stillnot entirely clear, but their continuous presence in the humanbloodstream gives them the opportunity to be associated withstill-unexplained disease processes. Previous small-scale studies havefound an increased level of these bacteria in the active stages ofseveral conditions, such as classical autoimmune diseases, multiplesclerosis, and chronic fatigue syndrome. The production of thesemonoclonal antibodies will allow development of more practical andspecific quantitative testing and should help establish links withdisease."
ZANN Corp. intends to establish collaborations to develop andmarket specific tests based on these antibodies. The market for thesetests remains to be established, but at least one million Americansare diagnosed with one of the conditions where elevated levels ofthese bacteria have been seen. It is expected that a specificquantitative test will have value for evaluating disease activity inthis population. As the testing system is developed and other studiesof pathogenicity are done, it is likely that additional diseaseassociations will be found.

ABOUT ZANN CORP.

ZANN Corp. manages our five main scalable technologies and systems- nutraceuticals, niche market vehicle sales, financial services,antibodies and gene therapy for potentially harmful bacterium whilemanaging performance. Each technology group is a profit centermeasured by its contribution to overall significant growth thatenables building a company with a diverse range of high quality, highvalue products and services for niche markets where we can excel.
For additional information please visit the corporate website at:www.zanncorp.com
Certain statements in this news release may containforward-looking information within the meaning of Rule 175 under theSecurities Act of 1933 and Rule 3b-6 under the Securities Exchange Actof 1934 and are subject to the safe harbor created by those rules. Allstatements, other than statements of fact, included in this release,including, without limitation, statements regarding potential futureplans and objectives of the company, are forward-looking statementsthat involve risks and uncertainties. There can be no assurance thatsuch statements will prove to be accurate and actual results andfuture events could differ materially from those anticipated in suchstatements.

--30--SLB/cl* CONTACT: ZANN Corp. Investor Relations, 810-714-2978 [e-mail] KEYWORD: MICHIGAN INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL BIOTECHNOLOGY SOURCE: ZANN Corp.Copyright Business Wire 2005

(c) 2005 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.

[ooy]

Bloss die Finger weg von diesem Scam.
Die splitten staendig, hier kann man nur verlieren.
Ich beobachte den Wert seit mehr als einem Jahr und kann nur jeden warnen, hier zu investieren!!

[64Dieter]

Zann ist heute nacht um mehr als 50 % angestiegen !!

Weiß jemand etwas genaues?


Oder ist dieser Kursanstieg ohne Bedeutung?

[Pepersack]

Press Release
Source: ZANN Corp.


ZANN Corp Announces Planned Acquisition
Wednesday April 6, 9:40 am ET

FENTON, Mich.--(BUSINESS WIRE)--April 6, 2005--ZANN Corp. (OTCBB:ZANC -
News) announced today that ZANN Corp (Zann) and Sartam Industries, Inc.
(Sartam) have signed a Letter of Intent (LOI) for the purpose of Zann acquiring
Sartam. Sartam has a semi-automatic riveting system which can run at more than
one rivet/second with a skilled operator.

According to Robert C. Simpson - CEO, "We believe this is the most advanced
semi-automatic riveting system in the world. Our preliminary sales goal for the first
24 months is for 1,000 tools at greater than $1,500.00 and 6,300,000 magazines at
greater than $3.00, for a combined total of approximately $20,250,000. These
figures represent less than 1% of the US market share for rivet guns."

Simpson went on to say, "This system represents superior quality and labor
savings of more than 40% in many cases. The tools weigh less than 4 pounds and
are portable. Zann and Sartam complement each other perfectly, and will create
unique synergies for both companies. Many of our team members, including me,
cut their teeth in the manufacturing-automation business. A definitive agreement
providing for the acquisition of Sartam is being written with the LOI as a guideline.
Our objective is to complete the financial audit during the 3rd Quarter 2005, and
acquire Sartam shortly thereafter."

ABOUT ZANN CORP

ZANN Corp. manages four wholly owned business units (two of these are in the
development stage) with scalable technologies and plans to acquire a fifth this
year. This diverse range of high quality, high value products and services are
aimed at profitable niche markets. For additional information please visit the
corporate website at: www.zanncorp.com

Certain statements in this news release may contain forward-looking information
within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6
under the Securities Exchange Act of 1934 and are subject to the safe harbor
created by those rules. All statements, other than statements of fact, included in
this release, including, without limitation, statements regarding potential future
plans and objectives of the company, are forward-looking statements that involve
risks and uncertainties. There can be no assurance that such statements will prove
to be accurate and actual results and future events could differ materially from
those anticipated in such statements.

[64Dieter]

Danke!!!


Die Meldung hört sich ja gar nicht so schlecht an.